A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates.

Qiao J, Lu G, Zhang HW, Chen H, Ma C, Olofsson JI, Witjes H, Heijnen E, Mannaerts B

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology20 Mar 2012Cited by 20 (Europe PMC)

PMID22429192DOI10.3109/09513590.2012.665103PepBankPUB-22429192

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese women undergoing ovarian stimulation, triptorelin required more rFSH than ganirelix.
In plain wordsIn Chinese women, triptorelin required more fertility-stimulating hormone than ganirelix.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaserFSH requirement
Study
n = 233
Comparator
Ganirelix
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
rFSH requirement
1416 IU
triptorelin
rFSH requirement
1272 IU
ganirelix
Source sentences
Summary
The amount of rFSH needed was significantly lower for ganirelix (1272 IU) vs. triptorelin (1416 IU; P< 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120).
Summary · context
The primary end point was the amount of recombinant follicle-stimulating hormone (rFSH) required to meet the human chorionic gonadotropin criterion (three follicles ≥17 mm).
Report a problemFND-2242919201
02HumanRandomized controlled trialEfficacy outcome
In Chinese women undergoing ovarian stimulation, ganirelix required less rFSH than triptorelin: 1272 versus 1416 IU (P<0.001).
In plain wordsIn Chinese women undergoing ovarian stimulation, ganirelix required less rFSH than triptorelin.
Peptide
Ganirelix
Outcome
DecreaserFSH requirement
Study
n = 233
Comparator
Triptorelin long protocol
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
rFSH requirement
1272 IU
ganirelix
rFSH requirement
1416 IU
triptorelin
P value
< 0.001
between groups
Source sentences
Summary
The amount of rFSH needed was significantly lower for ganirelix (1272 IU) vs. triptorelin (1416 IU; P< 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary end point was the amount of recombinant follicle-stimulating hormone (rFSH) required to meet the human chorionic gonadotropin criterion (three follicles ≥17 mm).
Summary · context
The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120).
Report a problemFND-2242919205
03HumanRandomized controlled trialEfficacy outcome
In Chinese women, ongoing pregnancy rates were 39.2% with triptorelin and 39.8% with ganirelix.
In plain wordsIn Chinese women, ongoing pregnancy rates were 39.2% with triptorelin and 39.8% with ganirelix.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeOngoing pregnancy per started cycle
Study
n = 233
Comparator
Ganirelix
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Ongoing pregnancy
39.2%
triptorelin
Ongoing pregnancy
39.8%
ganirelix
Source sentences
Summary
Ongoing pregnancy rates per started cycle were 39.8% (ganirelix) and 39.2% (triptorelin).
1 context sentence(design, population, supporting numbers)
Summary · context
The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120).
Report a problemFND-2242919202
04HumanRandomized controlled trialSafety outcome
In Chinese women, cancellation for OHSS risk occurred in 7.5% with triptorelin versus 1.8% with ganirelix (P = 0.06).
In plain wordsIn Chinese women, cancellation for ovarian hyperstimulation risk occurred in 7.5% with triptorelin versus 1.8% with ganirelix (P = 0.06).
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeCancellation for OHSS risk
Study
n = 233
Comparator
Ganirelix
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Cancellation for OHSS risk
7.5%
triptorelin
Cancellation for OHSS risk
1.8%
ganirelix
Source sentences
Summary
Although both treatments were well tolerated, cancellation due to risk of ovarian hyperstimulation syndrome (OHSS) was less frequent with ganirelix (1.8%) than triptorelin (7.5%) (P = 0.06).
1 context sentence(design, population, supporting numbers)
Summary · context
The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120).
Report a problemFND-2242919203
05HumanRandomized controlled trialSafety outcome
In Chinese women, triptorelin and ganirelix were well tolerated.
In plain wordsIn Chinese women, triptorelin and ganirelix were well tolerated.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTolerability
Study
n = 233
Comparator
Ganirelix
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
Although both treatments were well tolerated
1 context sentence(design, population, supporting numbers)
Summary · context
The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120).
Report a problemFND-2242919204
06HumanRandomized controlled trialEfficacy outcome
In Chinese women undergoing ovarian stimulation, ongoing pregnancy rates were 39.8% with ganirelix and 39.2% with triptorelin.
In plain wordsIn Chinese women undergoing ovarian stimulation, ongoing pregnancy rates were similar with ganirelix and triptorelin.
Peptide
Ganirelix
Outcome
IncreaseOngoing pregnancy per started cycle
Study
n = 233
Comparator
Triptorelin long protocol
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Ongoing pregnancy rate
39.8%
ganirelix
Ongoing pregnancy rate
39.2%
triptorelin
Source sentences
Summary
Ongoing pregnancy rates per started cycle were 39.8% (ganirelix) and 39.2% (triptorelin).
2 context sentences(design, population, supporting numbers)
Summary · context
Less rFSH was needed in the ganirelix protocol than the long GnRH agonist protocol, with fewer reported cases of OHSS and similar pregnancy rates.
Summary · context
The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120).
Report a problemFND-2242919206
07HumanRandomized controlled trialSafety outcome
In Chinese women undergoing ovarian stimulation, cancellation for OHSS risk occurred in 1.8% with ganirelix versus 7.5% with triptorelin (P=0.06).
In plain wordsIn Chinese women undergoing ovarian stimulation, cancellation for ovarian hyperstimulation risk was less frequent with ganirelix than triptorelin.
Peptide
Ganirelix
Outcome
DecreaseCancellation due to OHSS risk
Study
n = 233
Comparator
Triptorelin long protocol
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Measurements
Cancellation due to OHSS risk
1.8%
ganirelix
Cancellation due to OHSS risk
7.5%
triptorelin
P value
0.06
between groups
Source sentences
Summary
Although both treatments were well tolerated, cancellation due to risk of ovarian hyperstimulation syndrome (OHSS) was less frequent with ganirelix (1.8%) than triptorelin (7.5%) (P = 0.06).
1 context sentence(design, population, supporting numbers)
Summary · context
The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120).
Report a problemFND-2242919207
08HumanNon-randomized trialSafety outcome
In Chinese women undergoing ovarian stimulation, ganirelix was well tolerated, as was triptorelin.
In plain wordsIn Chinese women undergoing ovarian stimulation, ganirelix was well tolerated, as was triptorelin.
Peptide
Ganirelix
Outcome
Not applicableTolerability
Study
n = 113
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Although both treatments were well tolerated
1 context sentence(design, population, supporting numbers)
Summary · context
The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120).
Report a problemFND-2242919208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00725491

A Study to Assess the Efficacy and Safety of Ganirelix (Orgalutran®) Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for in Vitro Fertilization (IVF) or Intra Cytoplasmatic Sperm Injection (ICSI) (Study 38651)(P05703)

Organon and Con = 259May 2007 to Dec 2008

Controlled Ovarian Stimulation

Trial page ClinicalTrials.govUpdated 3 Feb 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC